Comparison Overview

Arch Pharmalabs, Ltd.

VS

Viatris

Arch Pharmalabs, Ltd.

"H" Wing, 4th Floor, Tex Centre, Andheri (E), Mumbai, undefined, 400 072, IN
Last Update: 2025-03-05 (UTC)

Founded in 1999,Arch Pharmalabs has gained recognition as a world-class provider of small molecule process chemistry, custom synthesis services and full life-cycle API and drug intermediates manufacture for the global pharmaceutical industry. Generating revenues of USD 200 million, our India-based offering is supported by 2,400 customer-centric Archers, eleven certified facilities (including cGMP-compliant, US FDA- and EDQM-approved sites) and two state-of-the-art Process Technology centres. Arch Pharmalabs works tirelessly to deliver value, innovation and effective supply chain solutions in the spirit of true partnership. Our large family of satisfied customers range from emerging or specialty companies to global majors, many of whom have designated Arch Pharmalabs as a Preferred Supplier or Strategic Partner. Arch Pharmalabs received CNBC TV Emerging India 2006 Award as the No.1 Small or Medium Company in the Pharmaceuticals and Chemicals category.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 678
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Viatris

Last Update: 2024-08-12 (UTC)
Between 750 and 799

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.twitter.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 16,525
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/arch-pharmalabs-ltd..jpeg
Arch Pharmalabs, Ltd.
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/viatris.jpeg
Viatris
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Arch Pharmalabs, Ltd.
100%
Compliance Rate
0/4 Standards Verified
Viatris
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Arch Pharmalabs, Ltd. in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Viatris in 2025.

Incident History — Arch Pharmalabs, Ltd. (X = Date, Y = Severity)

Arch Pharmalabs, Ltd. cyber incidents detection timeline including parent company and subsidiaries

Incident History — Viatris (X = Date, Y = Severity)

Viatris cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/arch-pharmalabs-ltd..jpeg
Arch Pharmalabs, Ltd.
Incidents

No Incident

https://images.rankiteo.com/companyimages/viatris.jpeg
Viatris
Incidents

No Incident

FAQ

Viatris company demonstrates a stronger AI Cybersecurity Score compared to Arch Pharmalabs, Ltd. company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Viatris company has disclosed a higher number of cyber incidents compared to Arch Pharmalabs, Ltd. company.

In the current year, Viatris company and Arch Pharmalabs, Ltd. company have not reported any cyber incidents.

Neither Viatris company nor Arch Pharmalabs, Ltd. company has reported experiencing a ransomware attack publicly.

Neither Viatris company nor Arch Pharmalabs, Ltd. company has reported experiencing a data breach publicly.

Neither Viatris company nor Arch Pharmalabs, Ltd. company has reported experiencing targeted cyberattacks publicly.

Neither Arch Pharmalabs, Ltd. company nor Viatris company has reported experiencing or disclosing vulnerabilities publicly.

Neither Arch Pharmalabs, Ltd. nor Viatris holds any compliance certifications.

Neither company holds any compliance certifications.

Viatris company has more subsidiaries worldwide compared to Arch Pharmalabs, Ltd. company.

Viatris company employs more people globally than Arch Pharmalabs, Ltd. company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Arch Pharmalabs, Ltd. nor Viatris holds SOC 2 Type 1 certification.

Neither Arch Pharmalabs, Ltd. nor Viatris holds SOC 2 Type 2 certification.

Neither Arch Pharmalabs, Ltd. nor Viatris holds ISO 27001 certification.

Neither Arch Pharmalabs, Ltd. nor Viatris holds PCI DSS certification.

Neither Arch Pharmalabs, Ltd. nor Viatris holds HIPAA certification.

Neither Arch Pharmalabs, Ltd. nor Viatris holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X